Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby powyżej 18. roku życia.
- •Pacjenci z zaawansowanym rakiem piersi (HR+/HER2-) u których choroba postąpiła pomimo wcześniejszego leczenia.
- •Pacjenci z zaawansowanym lub rozsianym rakiem potwierdzonym badaniami, z pewnym typem amplifikacji genu CCNE1.
- •W fazie II: Pacjenci z zaawansowanym rakiem piersi (HR+/HER2-) u których choroba postąpiła po leczeniu inhibitory aromatazy lub tamoksyfenem w połączeniu z inhibitorem CDK4/6.
✗ Disqualifies
- •Osoby, które wcześniej otrzymywały inhibitor CDK2.
- •Pacjenci z niewystarczającą funkcją szpiku kostnego lub narządów.
- •Osoby z poważnymi, niekontrolowanymi chorobami serca.
- •Osoby z objawowymi przerzutami do mózgu lub wymagającymi leczenia w ciągu ostatnich 2 tygodni.
- •W leczeniu skojarzonym: Pacjenci z objawową chorobą narządów wewnętrznych.
- •Kobiety w ciąży lub karmiące piersią, lub te, które nie chcą stosować skutecznej antykoncepcji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (33)
University of California LA
Los Angeles, United States
Florida Cancer Specialists
Fort Myers, United States
Dana Farber Cancer Institute
Boston, United States
WA Uni School Of Med
St Louis, United States
Memorial Sloan Kettering
New York, United States
SCRI Oncology Partners
Nashville, United States
MD Anderson Cancer Center Uni of Te
Houston, United States
Fred Hutch Cancer Research
Seattle, United States
Novartis Investigative Site
Clayton, Australia
Novartis Investigative Site
Melbourne, Australia
Novartis Investigative Site
Toronto, Canada
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Nanjing, China
Novartis Investigative Site
Xian, China
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Odense C, Denmark
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Modena, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Chuo Ku, Japan
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Tainan, Taiwan
Novartis Investigative Site
London, United Kingdom
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.